Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Common Equity (2016 - 2025)

Dare Bioscience's Common Equity history spans 11 years, with the latest figure at $2.8 million for Q4 2025.

  • For Q4 2025, Common Equity rose 147.28% year-over-year to $2.8 million; the TTM value through Dec 2025 reached $2.8 million, up 147.28%, while the annual FY2025 figure was $2.8 million, 147.28% up from the prior year.
  • Common Equity reached $2.8 million in Q4 2025 per DARE's latest filing, down from $2.9 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $38.8 million in Q4 2021 to a low of -$12.7 million in Q2 2025.
  • Average Common Equity over 5 years is $7.3 million, with a median of $2.9 million recorded in 2025.
  • Peak YoY movement for Common Equity: surged 3464.87% in 2021, then crashed 576.63% in 2025.
  • A 5-year view of Common Equity shows it stood at $38.8 million in 2021, then tumbled by 71.33% to $11.1 million in 2022, then plummeted by 145.42% to -$5.0 million in 2023, then decreased by 19.11% to -$6.0 million in 2024, then soared by 147.28% to $2.8 million in 2025.
  • Per Business Quant, the three most recent readings for DARE's Common Equity are $2.8 million (Q4 2025), $2.9 million (Q3 2025), and -$12.7 million (Q2 2025).